详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS

文献详情

资源类型：

作者：

机构： [1]Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR, [2]Department of Medical Oncology, National Cancer Center, Singapore/SG, [3]Department of Oncology, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD/AU, [4]Cancer Center of Sun Yat-Sen University, Guangzhou/CN, [5]Department of Oncology, Chris O’Brien Lifehouse, Camperdown, NSW/AU, [6]Department of Clinical Oncology, the Chinese University of Hong Kong, Hong Kong/CN, [7]Department of Oncology, McGill University Health Center, Montreal/CA, [8]Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei/TW, [9]West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen/DE, [10]Wakayama Medical University, Wakayama/JP, [11]Massachusetts General Hospital and Harvard Medical School, Boston, MA/US, [12]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/CN, [13]Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN, [14]Boehringer Ingelheim, Danmark A/s/DK, [15]Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT/US, [16]Hospital Universitario Doce de Octubre and Cnio, Madrid/ES

出处：

DOI：

ISSN：

关键词： afatinib EGFR NSCLC

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 [2]Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged >= 75 Years: Subgroup Analysis of LUX-Lung 7 [3]Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. [4]Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients [5]Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [6]Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. [7]Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma [8]重组腺病毒TRAIL基因联合抗EGFR靶向药物对肺癌细胞增殖的影响 [9]非小细胞肺癌分子靶向治疗的研究进展 [10]Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)